Condition
Non Small Cell Lung Cancer Stage III
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 12 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
12 shownClinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsNCT02622581 · 2015-12-01
RECRUITINGResponse and Toxicity Prediction by Microbiome Analysis After (Concurrent) ChemoradiotherapyNCT04711330 · 2022-09-01
ACTIVE_NOT_RECRUITINGStudy of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant TreatmentNCT05382052 · 2022-06-17
ACTIVE_NOT_RECRUITINGAccelerated Radio-Immunotherapy for Lung CancerNCT04577638 · 2021-03-30
COMPLETEDEfficacy and Safety of CRT, Durvalumab and Surgery for SSTNCT04465968 · 2020-09-01
NOT_YET_RECRUITINGA Real-world Study of Durvalumab for Lung Cancer in ChinaNCT04672759 · 2020-07-28
UNKNOWNTumor Mutational Burden in Lung Cancer PatientsNCT04289259 · 2020-06-10
TERMINATEDDurvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyNCT04392505 · 2020-05-11
ACTIVE_NOT_RECRUITINGHer2-positive Lung Cancer Treated With Dedicated DrugNCT03845270 · 2019-05-17
COMPLETEDHigh Intensity Functional Image Guided Vmat Lung EvasionNCT03569072 · 2018-07-01
COMPLETEDPrognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLCNCT03055715 · 2017-04-01
COMPLETEDAn International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income CountriesNCT02247713 · 2014-09-01
UNKNOWNCommon interventions
DurvalumabDRUG2CisplatinDRUG1concurrent radiotherapyRADIATION1data collectionOTHER1Durvalumab InjectionDRUG1Functionally adapted, dose escalated VMAT radiotherapyRADIATION1Nivolumab and Intensity Modulated Radiotherapy (IMRT)COMBINATION_PRODUCT1pertuzumab + trastuzumab + docetaxelDRUG1S1DRUG1SurgeryPROCEDURE1TMB assessmentOTHER1
Leading sponsors
AIO-Studien-gGmbH
1
Assistance Publique - Hôpitaux de Paris
1
Center Eugene Marquis
1
Fundación GECP
1
Intergroupe Francophone de Cancerologie Thoracique
1
Leiden University Medical Center
1
Martin-Luther-Universität Halle-Wittenberg
1
National Cancer Center Hospital East
1
Oslo University Hospital
1
Peking Union Medical College Hospital
1
Peter MacCallum Cancer Centre, Australia
1
The Netherlands Cancer Institute
1
Trial status mix
COMPLETED4
ACTIVE_NOT_RECRUITING3
UNKNOWN2
NOT_YET_RECRUITING1
RECRUITING1
TERMINATED1
Phase mix
PHASE23
NA1
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.